Eric Murphy, Alterome CEO

Mys­te­ri­ous Or­biMed-backed biotech nears $100M in fund­ing, hints at plans to go af­ter ‘un­drug­gable 3.0’

In Jan­u­ary, Al­terome launched from stealth — but re­mained quite stealthy. While the biotech put out a press re­lease for its $64 mil­lion Se­ries A, led by Or­biMed, it launched with­out a web­site and didn’t elab­o­rate on its sci­ence be­yond “al­ter­ation-spe­cif­ic tar­get­ed ther­a­pies for the treat­ment of can­cer.”

But with an ad­di­tion­al $35 mil­lion — bring­ing its to­tal Se­ries A to $99 mil­lion — Al­terome ap­pears more will­ing to share. For one, it now has a web­site, al­though the page doesn’t of­fer more than the bare-bones de­tails on the sci­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.